Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.LifeCycle Pharma has announced that interim results of an ongoing Phase II clinical trial for LCP-Tacro, an immunosuppressant for the treatment of kidney transplant patients, demonstrated a superior profile when compared to Prograf, including better pharmacokinetics, once-a-day tablet formulation and higher bioavailability.
Subscribe to our email newsletter
The company expects that the Phase II clinical trial will provide a robust statistical assessment, confirm the proposed dosing regimen and support the initiation of a Phase III clinical trial in 2008 in de-novo kidney and stable kidney transplant recipients. Top-line results from the Phase II clinical trial are expected by year end 2007 or early 2008.
The Phase II clinical trial, is a three sequence, open-label, multi-center, prospective, conversion study in stable kidney transplant patients to assess and compare the pharmacokinetics (Cmax, C24, and AUC), and safety of LCP-Tacro (tacrolimus) tablets once-a-day versus Prograf (tacrolimus) capsules twice-a-day.
Flemming Ornskov, president and CEO of LifeCycle Pharma, said: “The continued growth of our organ transplantation franchise is integral to the success of our business strategy of evolving into a fully integrated specialty pharmaceutical company. LCP-Tacro (kidney) in Phase II and LCP-Tacro (liver) nearing Phase II, demonstrates the successful execution of our strategy.”